In vitro antibacterial activity of eravacycline against multidrug-resistant Acinetobacter baumannii isolates

Year 2021, Volume: 25 Issue: 5, 549 - 553, 28.06.2025

Merve Ataman , Emel Mataracı Kara , Berna Özbek Çelik

Abstract

The antibacterial effectiveness of eravacycline was compared with various antibiotics used in Acinetobacter therapy against multidrug-resistant (MDR) Acinetobacter baumannii strains. Antibacterial susceptibility studiea was achieved by the broth microdilution method against 52 non–duplicate, A. baumanniii strains to eravacycline, tobramycin, levofloxacin, cefepime, meropenem, and colistin. Eravacycline presented greater action than the comparators of the other group, cefepime, colistin, levofloxacin, and tobramycin. While the MIC50/90 values of eravacycline were 8/16 mg/L and those for tobramycin, levofloxacin, cefepime, meropenem, and colistin were found 256/>256, 64/>256, 256/>256, 128/>256, and 0.5/256 mg/L, respectively. As a result, the present study showed that eravacycline was a potent effective antibiotic against MDR A. baumannii. Eravacycline could be an effective new alternative for use in particular, for the treatment of this problematic organism.a

Keywords

Non-fermentative , tetracycline , antibacterial agent , resistant bacteria , MIC

References

• [1] Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48: 1–12.
• [2] Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012; 3(3): 243-250.
• [3] Vrancianu CO, Gheorghe I, Czobor IB, Chifiriuc MC. Antibiotic Resistance Profiles, Molecular Mechanisms and Innovative Treatment Strategies of Acinetobacter baumannii. Microorganisms. 2020; 8(6): 935.
• [4] Chen CM, Ke SC, Li CR, Chang CC. The comparison of genotyping, antibiogram,and antimicrobial resistance genes between carbapenem-susceptible and -resistant Acinetobacter baumannii. Comp Immunol Microbiol Infect Dis. 2014; 37: 339–346.
• [5] Hammerum AM, Hansen F, Skov MN, Stegger M, Andersen PS, Holm A, Jakobsen L, Justesen US. Investigation of a possible outbreak of carbapenem-resistant Acinetobacter baumannii in Odense, Denmark using PFGE, MLST and whole-genome-based SNPs. J Antimicrob Chemother. 2015; 70: 1965–1968.
• [6] Dizbay M, Guzel Tunccan O, Ergut Sezer B, Hizel K. Nosocomial imipenem-resistant Acinetobacter baumannii infections: Epidemiology and risk factors. Sca J Infect Dis 2010; 741-746.
• [7] Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012; 67(7): 1607-1615.
• [8] Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016; 76: 567–588.
• [9] Livermore DM, Mushtaq S, Warner M, Woodford N. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016; 60: 3840–3844.
• [10]Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015; 59: 1802–1805.
• [11] Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100 Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2020.
• [12] European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters Version 11.0, valid from 2021-01-01.
• [13] Metan G, Zarakolu P, Otlu B, Tekin I, Aytaç H, Bölek EÇ, Metin BC, Arsava EM, Ünal S. Emergence of colistin and carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (CCR-Acb) complex in a neurological intensive care unit followed by successful control of the outbreak. J Infect Public Health. 2020; 13(4): 564-570.
• [14] Weinberg SE, Villedieu A, Bagdasarian N, Karah N, Teare L, Elamin WF. Control and management of multidrug resistant Acinetobacter baumannii: A review of the evidence and proposal of novel approaches. Infect Prevent Pract. 2020; 2(3): 100077.
• [15] Özcelik HB, Yildirim T, Marakli S, Önder İ. Investigation of oxacillinases type beta-lactamases in carbapenems resistant Acinetobacter baumannii clinical isolates. Rev Med Microbiol. 2020; 31(4): 209-214.
• [16] Karakonstantis S. A systematic review of implications, mechanisms, and stability of in vivo emergent resistance to colistin and tigecycline in Acinetobacter baumannii. J Chemother. 2020; 17: 1-11.
• [17] Hornsey M, Ellington MJ, Doumith M, Thomas CP, Gordon NC, Wareham DW, Quinn J, Lolans K, Livermore DM, Woodford N. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Antimicrob Chemother. 2010; 65: 1589–1593.
• [18] Bassetti M, Peghin M, Vena A, Giacobbe DR. Treatment of Infections Due to MDR Gram-Negative Bacteria. Front Med. 2019; 6: 74.
• [19] Mataracı-Kara E, Yılmaz M, Ozbek-Celik B. In-vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against Multi-Drug Resistant Acinetobacter baumannii isolates. J Glob Antimicrob Resist. 2019; 17: 137- 141.
• [20] Olesky M, Bassetti M, Corey R, Doi Y, Morrissey I, Grossman T, Olesky M, Scoble P, Sutcliffe J. In vitro global surveillance of eravacycline and comparators against Enterobacteriaceae, Acinetobacter baumannii, Stenotrophomonas maltophilia, including multidrug-resistant (MDR) isolates, over a three-year period (2013–15). Open Forum Infect Dis. 2016; 3(1): 1825.
• [21] Connors KP, Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Redican S, Nicolauet DP. Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women. Antimicrob Agents Chemother. 2014; 58(4): 2113–2118.